AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein CIP2A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TCG1

UPID:

CIP2A_HUMAN

Alternative names:

Cancerous inhibitor of PP2A; p90 autoantigen

Alternative UPACC:

Q8TCG1; A1L4J7; B9EGC3; Q6P4G6; Q8WVP8; Q96PI2; Q9H9C6; Q9P204

Background:

Protein CIP2A, also known as Cancerous inhibitor of PP2A and p90 autoantigen, plays a pivotal role in human malignancies. It functions as an oncoprotein by inhibiting PP2A and stabilizing MYC, which are crucial processes in the development and progression of cancer. This protein promotes anchorage-independent cell growth and tumor formation, highlighting its significance in oncogenesis.

Therapeutic significance:

Understanding the role of Protein CIP2A could open doors to potential therapeutic strategies. Its critical involvement in inhibiting PP2A and stabilizing MYC in cancer makes it a promising target for drug discovery efforts aimed at developing novel cancer therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.